Company Overview

Hypha Labs, Inc. (FUNI) is a publicly traded, early-stage life sciences and consumer wellness company operating primarily in the United States. The company focuses on the research, development, and commercialization of products derived from functional mushrooms and psychedelic compounds, with an emphasis on mental health, wellness, and alternative therapeutic applications. Its activities place it at the intersection of the biotechnology, consumer wellness, and emerging psychedelics industries.

The company’s business model centers on developing intellectual property, formulations, and branded products that leverage mushroom-based compounds, including non-psychoactive functional mushrooms and, where legally permissible, psychedelic substances for research and future therapeutic use. Hypha Labs positions itself as a platform company seeking early entry into regulated psychedelic and functional mushroom markets. The company evolved from earlier cannabis- and hemp-adjacent operations and rebranded to Hypha Labs, Inc. to align its strategy with the growing interest in alternative mental health treatments and mycology-based wellness solutions. Some historical disclosures regarding its exact operational scope and revenue composition are limited, and portions of its early evolution remain data inconclusive based on available public sources.

Business Operations

Hypha Labs operates as a development-stage company with activities focused on product formulation, intellectual property development, and strategic market positioning rather than large-scale commercial manufacturing. Revenue generation, where present, has historically been limited and inconsistent, reflecting its early-stage status. The company’s operations are primarily domestic, with no clearly disclosed material international revenue streams as of its most recent public filings.

The company controls branding assets, proprietary formulations, and early-stage research initiatives related to functional mushrooms and psychedelic compounds. Public disclosures reference exploratory partnerships and third-party relationships for research, product development, and potential distribution; however, specific long-term contracts, joint ventures, or revenue-producing subsidiaries are not consistently detailed. Based on available public information, data is inconclusive regarding the scale, durability, and financial contribution of these operational arrangements.

Strategic Position & Investments

Strategically, Hypha Labs aims to establish early exposure to the emerging psychedelics and functional mushroom sectors by building a portfolio of intellectual property, consumer-facing wellness concepts, and research-driven assets. Growth initiatives have included corporate restructuring, rebranding, and public market positioning intended to attract strategic partners and capital aligned with alternative mental health and wellness trends.

The company has disclosed intentions to pursue acquisitions, licensing arrangements, or strategic investments that complement its focus on mycology and psychedelic science. However, publicly verified information regarding completed material acquisitions, controlling stakes in operating subsidiaries, or revenue-generating portfolio companies is limited. As such, data is inconclusive based on available public sources regarding the financial impact of past investments or the near-term commercialization timeline of its emerging technologies.

Geographic Footprint

Hypha Labs is headquartered and primarily operates in the United States, with its corporate, regulatory, and strategic activities centered in U.S. jurisdictions. Its market focus aligns with regions where functional mushroom products are legally sold and where regulatory frameworks for psychedelic research are evolving.

While the company references global market opportunities in investor communications, there is no consistently verified evidence of material operations, assets, or revenue in Europe, Latin America, or Asia-Pacific. International influence at this stage appears limited to strategic intent rather than established operational presence, and data is inconclusive based on available public sources regarding sustained non-U.S. activities.

Leadership & Governance

Hypha Labs is led by a management team with experience in emerging growth sectors, public company operations, and alternative wellness markets. Leadership has articulated a strategic vision centered on early participation in regulated psychedelic markets, disciplined intellectual property development, and positioning the company for long-term value creation as legal frameworks mature.

Disclosures regarding executive leadership have varied across reporting periods, and the full composition of the senior management team is not consistently detailed in recent public filings. Based on the most consistently reported information:

• Yaron Shaltiel – Chief Executive Officer

Information regarding additional executive officers, founders, or long-tenured board members is data inconclusive based on available public sources, as roles and titles have not been uniformly disclosed across verified filings and market disclosures.